Skip to main content
SpringerLink
Log in

Acute Coronary Syndromes

  • Conference paper
Intensive Care Medicine

Abstract

The term acute coronary syndromes describes a spectrum of conditions including ST elevation or q wave myocardial infarction (also known as ‘STEMI’), non-q wave myocardial infarction (or ‘NSTEMI’) and unstable angina. Patients with these diagnoses represent a significant proportion of acute admissions and have a high mortality and morbidity. There have been significant developments recently in the understanding of these conditions, and a wide range of treatment strategies have been proposed. In this chapter, we aim to overview the pathophysiological processes underlying the conditions and to discuss how a practical approache to management can be derived given the current evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Zaman AG, Helft G, Worthley SG, Badimon JJ (2000) The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149: 251–266

    Article  PubMed  CAS  Google Scholar 

  2. Richardson PD, Davies MJ, Born GV (1989) Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 2: 941–944

    Article  PubMed  CAS  Google Scholar 

  3. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT (1993) Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation 87: 1179–1187

    Google Scholar 

  4. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH (2001) Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 134: 224–238

    Article  PubMed  CAS  Google Scholar 

  5. Farb A, Burke AP, Tang AL, et al (1996) Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93: 1354–1363

    Article  PubMed  CAS  Google Scholar 

  6. Davies MJ, Bland JM, Hangartner JR, Angelini A, Thomas AC (1989) Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 10: 203–208

    PubMed  CAS  Google Scholar 

  7. Giroud D, Li JM, Urban P, Meier B, Rutishauer W (1992) Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 69: 729–732

    Article  PubMed  CAS  Google Scholar 

  8. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343: 311–322

    Google Scholar 

  9. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2: 349–360

    Google Scholar 

  10. Collins R, Peto R, Baigent C, Sleight P (1997) Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 336: 847–860

    Article  PubMed  CAS  Google Scholar 

  11. Spinler SA, Mikhail PA (1997) Prehospital-initiated thrombolysis. Ann Pharmacother 31: 1339–1346

    PubMed  CAS  Google Scholar 

  12. Anonymous (1994) Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 89: 1545–1556

    Article  Google Scholar 

  13. Theroux P, Ouimet H, McCans J, et al (1988) Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319: 1105–1111

    Article  PubMed  CAS  Google Scholar 

  14. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Juneau M (1993) Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 88: 2045–2048

    Article  PubMed  CAS  Google Scholar 

  15. Theroux P, Waters D, Lam J, Juneau M, McCans J (1992) Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 327: 141–145

    Article  PubMed  CAS  Google Scholar 

  16. Antman EM, Fox KM (2000) Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum. Am Heart J 139: 461–475

    Google Scholar 

  17. Klein LW, Wahid F, Van den Berg BJ, Parrillo JE, Calvin JE (1997) Comparison of heparin therapy for lt; or = 48 hours to gt;48 hours in unstable angina pectoris. Am J Cardiol 79: 259–263

    Article  PubMed  CAS  Google Scholar 

  18. Hirsh J, Fuster V (1994) Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. Circulation 89: 1449–1468

    Google Scholar 

  19. Hirsh J, Levine MN (1992) Low molecular weight heparin. Blood 79: 1–17

    PubMed  CAS  Google Scholar 

  20. Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337: 688–698

    Article  PubMed  CAS  Google Scholar 

  21. Klein W, Buchwald A, Hillis SE, et al (1997) Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 96: 61–68

    Article  PubMed  CAS  Google Scholar 

  22. Cohen M, Demers C, Gurfinkel EP, et al (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 337: 447–452

    Article  PubMed  CAS  Google Scholar 

  23. Antman EM, McCabe CH, Gurfinkel EP, et al (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100: 1593–1601

    Article  PubMed  CAS  Google Scholar 

  24. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators (1999) Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 353: 429–438

    Google Scholar 

  25. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335: 775–782

    Google Scholar 

  26. Antman EM, Braunwald E (2001) A second look at bivalirudin. Am Heart J 142: 929–931

    Article  PubMed  CAS  Google Scholar 

  27. Smith P, Arnesen H, Holme I (1990) The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 323: 147–152

    Article  PubMed  CAS  Google Scholar 

  28. Cohen M, Adams PC, Parry G, et al (1994) Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 89: 81–88

    Article  PubMed  CAS  Google Scholar 

  29. Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M (1998) Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes ( OASIS) pilot study results. Circulation 98: 1064–1070

    Article  PubMed  CAS  Google Scholar 

  30. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339

    Google Scholar 

  31. Cairns JA, Gent M, Singer J, et al (1985) Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 313: 1369–1375

    Article  PubMed  CAS  Google Scholar 

  32. Balsano F, Rizzon P, Violi F, et al (1990) Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group. Circulation 82: 17–26

    Article  PubMed  CAS  Google Scholar 

  33. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494–502

    Article  PubMed  CAS  Google Scholar 

  34. The PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339: 436–443

    Article  Google Scholar 

  35. The PARAGON Investigators (1998) International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb/ IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 97: 2386–2395

    Article  Google Scholar 

  36. Topol EJ (2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357: 1905–1914

    Article  PubMed  CAS  Google Scholar 

  37. Boden WE, O’Rourke RA, Crawford MH, et al (1998) Outcomes in patients with acute nonQ-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital ( VANQWISH) Trial Investigators. N Engl J Med 338: 1785–1792

    Article  PubMed  CAS  Google Scholar 

  38. Fragmin and Fast Revascularisation during InStability in Coronary artery disease Investigators (1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 354: 708–715

    Google Scholar 

  39. Lagerqvist B, Safstrom K, Stahle E, Wallentin L, Swahn E (2001) Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol 38: 41–48

    Article  PubMed  CAS  Google Scholar 

  40. Anonymous (1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349: 1429–1435

    Article  Google Scholar 

  41. Cannon CP, Weintraub WS, Demopoulos LA, et al (2001) Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/Illa inhibitor tirofiban. N Engl J Med 344: 1879–1887

    Article  PubMed  CAS  Google Scholar 

  42. Grines CL, Browne KF, Marco J, et al (1993) A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 328: 673–679

    Article  PubMed  CAS  Google Scholar 

  43. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H (1993) A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 328: 680–684

    Article  PubMed  CAS  Google Scholar 

  44. Zijlstra F, Hoorntje JC, de Boer MJ, et al (1999) Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 341: 1413–1419

    Article  PubMed  CAS  Google Scholar 

  45. Zahn R, Schiele R, Schneider S, et al (2001) Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: can we define subgroups of patients benefiting most from primary angioplasty? Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction Registry and the Myocardial Infarction Registry. J Am Coll Cardiol 37: 1827–1835

    Article  PubMed  CAS  Google Scholar 

  46. Yusuf S, Pogue J (1997) Primary angioplasty compared with thrombolytic therapy for acute myocardial infarction. JAMA 278: 2110–2111

    Article  PubMed  CAS  Google Scholar 

  47. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators (1997) A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 336: 1621–1628

    Google Scholar 

  48. Magid DJ, Calonge BN, Rumsfeld JS, et al (2000) Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA 284: 3131–3138

    Article  PubMed  CAS  Google Scholar 

  49. McCullough PA, O’Neill WW, Graham M, et al (1998) A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion ( MATE) trial. J Am Coll Cardiol 32: 596–605

    Article  PubMed  CAS  Google Scholar 

  50. The TIMI Study Group (1989) Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 320: 618–627

    Google Scholar 

  51. Gibson CM, Cannon CP, Greene RM, et al (1997) Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. Am J Cardiol 80: 21–26

    Article  PubMed  CAS  Google Scholar 

  52. Cannon CP, Gibson CM, Lambrew CT, et al (2000) Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 283: 2941–2947

    Article  PubMed  CAS  Google Scholar 

  53. Touboul P, Bonnefoy E (1998) [Comparison of primary angioplasty and prehospital thrombolysis in the acute phase of myocardial infarction. CAPTIM Study Group]. Arch Mal Coeur Vaiss 91 Spec No 2: 33–38

    Google Scholar 

  54. Jonas MA, Oates JA, Ockene JK, Hennekens CH (1992) Statement on smoking and cardiovascular disease for health care professionals. American Heart Association. Circulation 86: 1664–1669

    Article  PubMed  CAS  Google Scholar 

  55. Hansson L, Zanchetti A, Carruthers SG, et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755–1762

    Article  PubMed  CAS  Google Scholar 

  56. Anonymous (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389

    Google Scholar 

  57. Vaughan CJ, Murphy MB, Buckley BM (1996) Statins do more than just lower cholesterol. Lancet 348: 1079–1082

    Article  PubMed  CAS  Google Scholar 

  58. O’Driscoll G, Green D, Taylor RR (1997) Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95: 1126–1131

    Article  PubMed  Google Scholar 

  59. Notarbartolo A, Davi G, Averna M, et al (1995) Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 15: 247–251

    Article  PubMed  CAS  Google Scholar 

  60. Schwartz GG, Olsson AG, Ezekowitz MD, et al (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711–1718

    Article  PubMed  CAS  Google Scholar 

  61. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH (2001) Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program ( CHAMP ). Am J Cardiol 87: 819–822

    Google Scholar 

  62. Freemantle N, Cleland J, Young P, Mason J, Harrison J (1999) beta Blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 318: 1730–1737

    Google Scholar 

  63. First International Study of Infarct Survival Collaborative Group (1986) Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2: 57–66

    Google Scholar 

  64. Yusuf S, Wittes J, Friedman L (1988) Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 260: 2259–2263

    Google Scholar 

  65. Krumholz HM, Radford MJ, Wang Y, Chen J, Marciniak TA (1999) Early beta-blocker therapy for acute myocardial infarction in elderly patients. Ann Intern Med 131: 648–654

    Article  PubMed  CAS  Google Scholar 

  66. Latini R, Maggioni AP, Flather M, Sleight P, Tognoni G (1995) ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 92: 3132–3137

    Google Scholar 

  67. Lonn EM, Yusuf S, Jha P, et al (1994) Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90: 2056–2069

    Article  PubMed  CAS  Google Scholar 

  68. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145–153

    Google Scholar 

  69. Anonymous (1990) Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II). Am J Cardiol 66: 779–785

    Article  Google Scholar 

  70. The Multicenter Diltiazem Postinfarction Trial Research Group (1988) The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 319: 385–392

    Google Scholar 

  71. Thadani U, Opie LH (1994) Nitrates for unstable angina. Cardiovasc Drugs Ther 8: 719–726

    Article  PubMed  CAS  Google Scholar 

  72. Yusuf S, Collins R, MacMahon S, Peto R (1988) Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1: 1088–1092

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. F. Coutts
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. R. Redwood
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Rhodes
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care, Erasme Hospital, Free University of Brussels, Route de Lennik 808, B-1070, Brussels, Belgium

    Jean-Louis Vincent MD, PhD, FCCM, FCCP (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Coutts, J.F., Redwood, S.R., Rhodes, A. (2003). Acute Coronary Syndromes. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-5548-0_38

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-5548-0_38

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4757-5550-3

  • Online ISBN: 978-1-4757-5548-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation